Featured Research

from universities, journals, and other organizations

Less-Expensive Diuretics Found Superior In Treatment Of Hypertension

Date:
December 23, 2002
Source:
Wake Forest University Baptist Medical Center
Summary:
A major clinical trial of blood pressure medications has concluded that an inexpensive diuretic (water pill) is more effective in treating high blood pressure and preventing cardiovascular disease than newer more expensive medications.

WINSTON-SALEM, N.C. – A major clinical trial of blood pressure medications has concluded that an inexpensive diuretic (water pill) is more effective in treating high blood pressure and preventing cardiovascular disease than newer more expensive medications.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), conducted from February 1994 though March 2002, compared the drugs for use in starting treatment for high blood pressure.

"The preferred drug is the diuretic for three reasons. It provides better control of hypertension; it reduces complications from hypertension--particularly heart failure-- more effectively; and it is 10 to 20 times less expensive than the other drugs used in the trial," said Curt Furberg, M.D., Ph.D., of Wake Forest University Baptist Medical Center, chairman of the study's steering committee.

ALLHAT is the largest study ever to compare different types of hypertension drugs. It included more than 33,000 participants age 55 years or older at 623 clinical sites in North America. All the patients had hypertension and at least one other coronary heart disease risk factor. Approximately 50 percent of the participants were women and 35 percent were African-American.

"The bottom line is ALLHAT has shown that it matters which drug you use to control hypertension," said Furberg.

Participants were randomly assigned to receive the diuretic chlorthalidone, amlodipine (a calcium channel blocker sold under the name Norvasc) or lisinopril, (an angiotensin-converting enzyme (ACE) inhibitor sold under the names Prinivil and Zestril.)

In 2000, another drug used in the trial, doxazosin (an alpha-blocker sold under the name Cardura) was pulled from the trial because it was determined early in ALLHAT that it was not as effective as the less expensive diuretic medication.

The study does not recommend that patients stop taking their medication if they are using a drug other than a diuretic. However they are encouraged to speak with their physicians about adding or switching to a diuretic for their treatment.

ALLHAT's findings indicate that most patients will need more than one drug to adequately control their blood pressure and one of the drugs should be a diuretic. The National Heart, Lung and Blood Institute, part of the National Institutes of Health, supported the study.


Story Source:

The above story is based on materials provided by Wake Forest University Baptist Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Wake Forest University Baptist Medical Center. "Less-Expensive Diuretics Found Superior In Treatment Of Hypertension." ScienceDaily. ScienceDaily, 23 December 2002. <www.sciencedaily.com/releases/2002/12/021223084823.htm>.
Wake Forest University Baptist Medical Center. (2002, December 23). Less-Expensive Diuretics Found Superior In Treatment Of Hypertension. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2002/12/021223084823.htm
Wake Forest University Baptist Medical Center. "Less-Expensive Diuretics Found Superior In Treatment Of Hypertension." ScienceDaily. www.sciencedaily.com/releases/2002/12/021223084823.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins